Anti-CD160 antibodies are immunoglobulins that specifically recognize and bind CD160, the gene encoding the CD160 antigen in humans. In research applications, these antibodies are used to detect CD160 in tissue samples, cell lysates, and cultured cells. CD160 is a receptor expressed on natural killer cells and subsets of T cells that delivers stimulatory or inhibitory signals depending on its GPI-anchored or transmembrane form, and it recognizes classical and non-classical MHC class I molecules. Because CD160 signaling shapes NK and T cell activation, it is frequently examined in immune surveillance and cancer immunology research.
Catalog highlights and purchasing considerations
About the Biocompare CD160 antibody catalog
The Biocompare antibody search tool lists CD160 antibodies from a wide range of suppliers, with western blot, flow cytometry, and ELISA among the most common validated applications. Listings may also appear under the alternate name By55, an earlier designation for the same receptor. Several CD160 antibodies mentioned here have been cited across a range of immunology research, including studies on immune profiling of cancer-associated thrombosis, microRNA-29a regulation of stem-like CD8 T cell differentiation, and proteostasis mechanisms sustaining tumor-infiltrating lymphocyte function. Antibody reviews written by individual researchers have discussed unique immunodetection studies involving CD160, such as flow cytometric detection of CD160-positive lymphocyte populations.
Considerations when choosing a CD160 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.